Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics reported its Q3 2025 earnings on November 13, 2025, with an actual EPS of -$0.080 USD, and Q4 2025 earnings were released on March 17, 2026, reporting an actual EPS of -$0.060 USD, beating the consensus estimate of -$0.10. The company announced positive results from its Phase 2b CORAL trial for chronic cough in IPF patients and its Phase 2a RIVER trial for refractory chronic cough. The stock has seen significant movement, with a 52-week range between $4.85 and $14.39, and as of April 8, 2026, the share price was $13.07, representing a 142.04% increase from April 9, 2025.

As a clinical-stage biopharmaceutical company developing investigational therapies, Trevi Therapeutics, Inc. does not currently have commercial products on the market, therefore, there is no established demand seasonality for its products or services.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio™, an investigational therapy for neurologically mediated conditions, specifically chronic cough in adults with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), and chronic pruritus associated with prurigo nodularis. Haduvio functions as a dual kappa-opioid receptor agonist and mu-opioid receptor antagonist.

Trevi Therapeutics, Inc. is headquartered in New Haven, Connecticut, USA, and was founded in 2011, incorporated under the laws of the State of Delaware. The company conducts clinical trials internationally, with its Phase 2b CORAL trial having regulatory approval in 8 of 10 expected countries. Specific information regarding a broader commercial geographic footprint is not available as it is a clinical-stage company.

Trevi Therapeutics has a news sentiment score of 0.62. Analyst ratings indicate a generally positive outlook, with a consensus rating of "Buy" and an average rating score of 3.00, based on 2 strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating. There is no specific information available regarding events that have negatively affected Trevi Therapeutics, Inc.'s brand reputation in the past year.

Trevi Therapeutics, Inc. has significant institutional ownership, with 184 institutional owners and shareholders holding a total of 129,774,592 shares. Major institutional shareholders include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., BlackRock, Inc., Fmr Llc, and Vanguard Group Inc. Hedge funds own approximately 7.2% of the shares. Forest Baskett is the largest individual shareholder, owning 22.69 million shares, representing 17.68% of the company. The general public holds about 22% ownership.